NYXH
Nyxoah SA

378
Mkt Cap
$123.13M
Volume
6,381.00
52W High
$8.64
52W Low
$2.77
PE Ratio
-1.06
NYXH Fundamentals
Price
$2.77
Prev Close
$2.82
Open
$2.79
50D MA
$4.14
Beta
0.69
Avg. Volume
55,353.03
EPS (Annual)
-$2.67
P/B
2.10
$175.87
Loading...
Loading...
News
all
press releases
Nyxoah SA (NASDAQ:NYXH) Receives Consensus Rating of "Moderate Buy" from Brokerages
Nyxoah SA (NASDAQ:NYXH - Get Free Report) has been given a consensus rating of "Moderate Buy" by the five ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has...
MarketBeat·7h ago
News Placeholder
More News
News Placeholder
Nyxoah's (NYXH) Overweight Rating Reaffirmed at Cantor Fitzgerald
Cantor Fitzgerald reiterated an "overweight" rating and set a $11.00 price objective on shares of Nyxoah in a research report on Monday...
MarketBeat·7d ago
News Placeholder
Nyxoah Details Early U.S. Genio Launch, Reimbursement Update at Oppenheimer MedTech Conference 2026
Nyxoah (NASDAQ:NYXH) used its presentation at Oppenheimer's MedTech and Services Conference 2026 to outline the company's early U.S. launch progress for its Genio system, a neuromodulation therapy...
MarketBeat·9d ago
News Placeholder
Stifel Nicolaus Issues Pessimistic Forecast for Nyxoah (NASDAQ:NYXH) Stock Price
Stifel Nicolaus lowered their price target on Nyxoah from $11.00 to $10.00 and set a "buy" rating for the company in a report on Friday...
MarketBeat·10d ago
News Placeholder
Nyxoah (NASDAQ:NYXH) Issues Quarterly Earnings Results, Misses Expectations By $0.04 EPS
Nyxoah (NASDAQ:NYXH - Get Free Report) posted its earnings results on Thursday. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.65) by ($0.04). The company had revenue of $6.62 million for the quarter, compared to analyst estimates...
MarketBeat·11d ago
News Placeholder
Nyxoah (NYXH) Q4 2025 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·11d ago
News Placeholder
Nyxoah Q4 Earnings Call Highlights
Nyxoah (NASDAQ:NYXH) used its fourth-quarter and full-year 2025 earnings call to outline the first results from the U.S. launch of its Genio hypoglossal nerve stimulation system, discuss the evolving reimbursement environment for the category, and provide initial growth expectations for early 2026...
MarketBeat·11d ago
News Placeholder
Nyxoah SA (NYXH) Reports Q4 Loss, Misses Revenue Estimates
Nyxoah (NYXH) delivered earnings and revenue surprises of -4.62% and -2.46%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·11d ago
News Placeholder
KORU Medical Systems, Inc. (KRMD) Reports Q4 Loss, Beats Revenue Estimates
KORU Medical Systems, Inc. (KRMD) delivered earnings and revenue surprises of +50.00% and +0.05%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·18d ago
News Placeholder
Nyxoah SA (NASDAQ:NYXH) Receives Average Rating of "Moderate Buy" from Brokerages
Shares of Nyxoah SA (NASDAQ:NYXH - Get Free Report) have received an average rating of "Moderate Buy" from the five analysts that are currently covering the firm, MarketBeat Ratings reports. One...
MarketBeat·25d ago
<
1
2
...
>

Latest NYXH News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.